Hosted on MSN
CVKD: Designing phase 3 trial for CAD-1005 in HIT
Planning for Phase 3 Registration Trial of CAD-1005 in HIT On April 30, 2026, Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) announced an ‘End-of-Phase 2’ meeting with the U.S. Food and Drug ...
In this free webinar, learn how adaptive study designs can eliminate white space and accelerate the path from first-in-human (FIH) to proof-of-concept (POC). The featured speaker will share how ...
Toxicity monitoring in phase I/II clinical trials with applications at James Graham Brown Cancer Center Clinical Trials. This is an ASCO Meeting Abstract from the 2014 ASCO Annual Meeting I. This ...
Designing Dose-Finding Phase I Clinical Trials: Top 10 Questions That Should Be Discussed With Your Statistician Shing M. Lee, Nolan A. Wages, Karyn A. Goodman, A. Craig Lockhart JCO Precision ...
On April 30, 2026, Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) announced an 'End-of-Phase 2' meeting with the U.S. Food and Drug Administration (FDA) in which the agency provided critical guidance on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results